ATE188708T1 - Antikörperderivate - Google Patents

Antikörperderivate

Info

Publication number
ATE188708T1
ATE188708T1 AT92810633T AT92810633T ATE188708T1 AT E188708 T1 ATE188708 T1 AT E188708T1 AT 92810633 T AT92810633 T AT 92810633T AT 92810633 T AT92810633 T AT 92810633T AT E188708 T1 ATE188708 T1 AT E188708T1
Authority
AT
Austria
Prior art keywords
cancer
antibodies derivatives
antibodies
derivatives
hiv
Prior art date
Application number
AT92810633T
Other languages
English (en)
Inventor
Mau Sung Co
Hans Loibner
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919118013A external-priority patent/GB9118013D0/en
Priority claimed from GB929204514A external-priority patent/GB9204514D0/en
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE188708T1 publication Critical patent/ATE188708T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92810633T 1991-08-21 1992-08-18 Antikörperderivate ATE188708T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919118013A GB9118013D0 (en) 1991-08-21 1991-08-21 Monoclonal antibodies and their use
GB929204514A GB9204514D0 (en) 1992-03-02 1992-03-02 Monoclonal antibodies and their use

Publications (1)

Publication Number Publication Date
ATE188708T1 true ATE188708T1 (de) 2000-01-15

Family

ID=26299429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92810633T ATE188708T1 (de) 1991-08-21 1992-08-18 Antikörperderivate

Country Status (10)

Country Link
US (1) US5562903A (de)
EP (1) EP0528767B1 (de)
JP (1) JP3474592B2 (de)
AT (1) ATE188708T1 (de)
CA (1) CA2076432C (de)
DE (1) DE69230545T2 (de)
DK (1) DK0528767T3 (de)
ES (1) ES2145004T3 (de)
GR (1) GR3032944T3 (de)
PT (1) PT528767E (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0644947B1 (de) * 1992-05-22 1999-04-21 Novartis AG Antiidiotypische monoklonale antikörper gegen den lewis y-spezifischen monoklonalen antikörper br55-2 und deren verwendungen
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
EP0781847A1 (de) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanisierter monoklonaler Antikörper
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
JP2002540764A (ja) * 1999-02-12 2002-12-03 ジェネティックス・インスチチュート・インコーポレーテッド Ｂ７分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
AT413486B (de) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
AT413487B (de) 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
AT500648B1 (de) 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
US7780992B2 (en) * 2002-12-08 2010-08-24 Tareq Abduljalil Albahri Antiviral medicament
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
AU2004321433B2 (en) * 2004-07-14 2011-07-21 Greenovation Biotech Gmbh N-glycosylated antibody
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
EP1844074B1 (de) * 2005-02-03 2013-04-24 Antitope Limited Menschliche antikörper und proteine
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
PE20080262A1 (es) 2006-05-25 2008-04-30 Glaxo Group Ltd Anticuerpo humanizado contra interleuquina-18
KR101510753B1 (ko) 2006-06-07 2015-04-10 바이오얼라이언스 씨.브이. 암세포 상에서 발현되는 ｃｄ-43 및 ｃｅａ 상의 에피토프를 함유하는 탄수화물을 인식하는 항체 및 이를 이용하는 방법
EP1878747A1 (de) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-hergestellte Antikörper
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
CA2832111A1 (en) * 2006-12-20 2008-07-03 Mmrglobal, Inc. Antibodies and methods for making and using them
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
CA2706502C (en) 2007-12-18 2018-08-07 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2261254A3 (de) 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
EA036059B1 (ru) * 2007-12-28 2020-09-21 Протена Байосайенсиз Лимитед Способ получения антитела или его фрагмента, которое специфически связывается с агрегированным амилоидным белком
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN102272319B (zh) * 2009-01-08 2014-08-27 伯乐实验室公司 用于提高核酸扩增反应效率的方法和组合物
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
PL2485761T3 (pl) 2009-10-09 2019-10-31 Armagen Inc Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
EP2569013B1 (de) * 2010-05-14 2016-11-23 The Board of Trustees of the Leland Stanford Junior University Humanisierte und chimäre monoklonale antikörper gegen cd47
EP2407487A1 (de) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispezifische modulare Antikörper
JP2012067106A (ja) * 2011-10-14 2012-04-05 Greenovation Biotech Gmbh グリコシル化抗体
JP6266529B2 (ja) 2011-12-02 2018-01-24 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおけるアリールスルファターゼａ活性を増加するための方法および組成物
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3471759A1 (de) 2016-06-15 2019-04-24 Novartis AG Verfahren zur behandlung einer erkrankung mithilfe von inhibitoren von knochenmorphogenetischem protein 6 (bmp6)
CN109266656B (zh) * 2018-10-10 2021-02-19 江苏集萃药康生物科技股份有限公司 一种PD1人源化BALB/c小鼠模型的构建方法及其应用
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0256654B1 (de) * 1986-07-07 1996-09-18 Centocor, Inc. Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
DE4025499A1 (de) * 1990-08-11 1992-02-13 Sandoz Ag Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen

Also Published As

Publication number Publication date
CA2076432C (en) 2003-10-21
DE69230545T2 (de) 2000-07-06
ES2145004T3 (es) 2000-07-01
EP0528767A1 (de) 1993-02-24
US5562903A (en) 1996-10-08
DE69230545D1 (de) 2000-02-17
EP0528767B1 (de) 2000-01-12
DK0528767T3 (da) 2000-04-17
CA2076432A1 (en) 1993-02-22
PT528767E (pt) 2000-06-30
GR3032944T3 (en) 2000-07-31
JP3474592B2 (ja) 2003-12-08
JPH05336989A (ja) 1993-12-21

Similar Documents

Publication Publication Date Title
ATE188708T1 (de) Antikörperderivate
DE68923027D1 (de) Antigene.
DK69890D0 (da) Monoklonale antistoffer, der er reaktive med cachetin
DE3783277D1 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
GR3026219T3 (en) Mouse monoclonal antibodies
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
EP0198086A4 (de) Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikörpern, deren herstellung und antivirale menschliche monoklonale antikörper.
NO870476L (no) Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater.
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
DE3485712D1 (de) Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren.
AU584690B2 (en) E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma
DE69119591D1 (de) Das von mca-28a32 erkannte antigen
DK513687A (da) Monoklonale antistoffer over for ifn-omega, fremgangsmaade til deres fremstilling og deres anvendelse til rensning samt paavisning af ifn-omega
DE3584280D1 (de) Monoklonaler antikoerper gegen menschlichen krebs.
FI945485A (fi) Monoklonaaliset vasta-aineet ja niiden käyttö
DE69232140D1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
EP0334076A3 (en) Monoclonal antibody capable of recognizing an antigen associated with human arteriosclerosis, and process for preparing the same
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
DE68913601D1 (de) Monoklonaler Antikörper gegen menschliches Lungenadenokarzinom.
FI883765A (fi) Antikroppar mot biologiskt aktiva polypeptider och deras anvaendning vid diagnostiska foerfaranden.
NO952506L (no) Antistoffpreparater mot homogent minaktivin og anvendelse derav for påvisning av minaktivin i humane kroppsvæsker
AU2687992A (en) Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof
DE68913872D1 (de) Monoklonale Antikörper gegen den menschlichen Epidermal-Wachstumsfaktor mit hohem Molekulargewicht.
MX9705445A (es) Anticuerpos monoclonales anti-cd6 y su usos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification